Heir to the Throne: CEO Succession

Authored by Kai Peters, Pro-Vice-Chancellor (Faculty of Business and Law), Coventry University Group

Speculation about a CEO’s departure begins the day of a new CEO’s appointment. For many, planning succession is a natural part of their role as steward; for others, the thought of shaping plans for their own redundancy breeds paranoia. In this article, leadership expert Kai Peters finds a parallel between the perceptions of some modern CEOs towards succession and those of Louis XV of France.

This article also features comments from Simon Howard and Tom Taylor.

Share this with your Community



Contributors
Simon Howard
Non-executive Director

Tom Taylor
Board Mentor
Criticaleye


Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

Building an AI-Ready Workforce

AI is reshaping ways of working faster than most organisations can adapt, putting talent strategy at the top of the Board agenda. Criticaleye's Anna Mitchell asks Board Leaders and CPOs with hands-on experience o...


Click here to download this insight

Driving the Next Phase of Growth at RAC

In this interview with Criticaleye Senior Editor Jacob Ambrose Willson, RAC’s CFO, Jo Baker, talks through how she has helped to steer the business through a significant transformation during the last several year...


Richard Williams, Former CHRO at Western Union: How HR Becomes a Board-Level Power Function

Richard Williams, Board Mentor at Criticaleye and former Chief Human Resources Officer (CHRO) at Western Union joins Bridgette Hall, Senior Editor at Criticaleye to explore what it takes to lead HR in a global organi...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 232




British Land AlixPartners London Stock Exchange Group Rolls-Royce Stream Legal & General Global Payments Lightsource bp E.ON UK Mayborn Group Hitachi Solutions Southern Water NatWest Group LACE Partners Drax Group plc GlaxoSmithKline plc NATS Aldermore Group